Press releases
Titre paragraphe 1 EN
résumé EN
Half-year results 2024
Spineway, a specialist in innovative implants for the treatment of severe spinal pathologies, continues its organic growth (without scope effect) and achieves a turnover of €6.5 million for the first half of 2024, up 20% compared to S1 2023. The gross margin remains at a normative level of 69%, stable compared to the end of 2023 and in line with the Group's forecasts.
Press releases